Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Dose Escalation in ITP Non-Responders
NCT01880047Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2013
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by Weill Cornell Medicine. Started Feb 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01880047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01880047.